Abpro Bio Co., Ltd. (KOSDAQ:195990)
South Korea · Delayed Price · Currency is KRW 1,400.00
0.00 (0.00%)
At close: Feb 19, 2026
Abpro Bio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 36,183 | 31,663 | 25,375 | 22,112 | 32,914 | 35,797 |
Other Revenue | 0 | - | - | -0 | - | - |
| 36,183 | 31,663 | 25,375 | 22,112 | 32,914 | 35,797 | |
Revenue Growth (YoY) | 31.98% | 24.78% | 14.76% | -32.82% | -8.05% | 12.11% |
Cost of Revenue | 34,553 | 31,047 | 24,107 | 20,493 | 28,986 | 30,195 |
Gross Profit | 1,630 | 616.3 | 1,269 | 1,619 | 3,928 | 5,602 |
Selling, General & Admin | 11,056 | 9,246 | 8,269 | 8,544 | 7,848 | 4,974 |
Research & Development | 394.73 | 448.27 | 573.04 | 879.91 | 562.3 | 519.15 |
Amortization of Goodwill & Intangibles | 294.53 | 73.65 | 5.24 | 1.47 | 60.63 | 64.33 |
Other Operating Expenses | 257.04 | 444.94 | 323.52 | 251.64 | 433.14 | 335.11 |
Operating Expenses | 8,961 | 7,159 | 11,444 | 12,813 | 9,261 | 7,493 |
Operating Income | -7,331 | -6,543 | -10,175 | -11,193 | -5,333 | -1,891 |
Interest Expense | -1,584 | -2,090 | -2,341 | -4,591 | -6,859 | -4,946 |
Interest & Investment Income | 626.34 | 654.29 | 301.52 | 167.66 | 576.37 | 468.58 |
Earnings From Equity Investments | -63,734 | -27,881 | -9,377 | 4,219 | -5,876 | -12,984 |
Currency Exchange Gain (Loss) | 3,920 | 7,204 | 520.54 | 1,760 | 2,388 | -1,179 |
Other Non Operating Income (Expenses) | -44.31 | 2,986 | -1,015 | -867.14 | 8,613 | -19,725 |
EBT Excluding Unusual Items | -68,148 | -25,669 | -22,086 | -10,505 | -6,491 | -40,257 |
Gain (Loss) on Sale of Investments | 1.01 | 0.58 | 16.29 | 2,520 | - | - |
Gain (Loss) on Sale of Assets | -21.89 | 11,804 | -2,559 | 328.51 | 650.04 | -190.14 |
Asset Writedown | -2,195 | -2,191 | -1,029 | -487.48 | -3,834 | -759.42 |
Pretax Income | -70,364 | -16,056 | -25,658 | -8,145 | -9,675 | -41,207 |
Income Tax Expense | -334.95 | -426.12 | 84.12 | - | 64.59 | 3,548 |
Earnings From Continuing Operations | -70,029 | -15,629 | -25,742 | -8,145 | -9,740 | -44,755 |
Earnings From Discontinued Operations | - | - | - | - | -775.31 | -16,862 |
Net Income to Company | -70,029 | -15,629 | -25,742 | -8,145 | -10,515 | -61,617 |
Minority Interest in Earnings | - | - | - | - | 484.68 | 2,645 |
Net Income | -70,029 | -15,629 | -25,742 | -8,145 | -10,030 | -58,972 |
Net Income to Common | -70,029 | -15,629 | -25,742 | -8,145 | -10,030 | -58,972 |
Shares Outstanding (Basic) | 28 | 28 | 28 | 27 | 25 | 21 |
Shares Outstanding (Diluted) | 28 | 29 | 28 | 27 | 27 | 21 |
Shares Change (YoY) | 0.03% | 4.78% | 3.72% | -0.50% | 25.82% | 64.14% |
EPS (Basic) | -2459.52 | -549.00 | -925.06 | -303.58 | -398.47 | -2767.28 |
EPS (Diluted) | -2497.07 | -572.73 | -925.10 | -303.60 | -433.06 | -3044.25 |
Free Cash Flow | -21,898 | -22,861 | -6,011 | -12,593 | -2,762 | 2,490 |
Free Cash Flow Per Share | -769.08 | -784.09 | -216.00 | -469.40 | -102.45 | 116.20 |
Gross Margin | 4.50% | 1.95% | 5.00% | 7.32% | 11.93% | 15.65% |
Operating Margin | -20.26% | -20.66% | -40.10% | -50.62% | -16.20% | -5.28% |
Profit Margin | -193.54% | -49.36% | -101.45% | -36.83% | -30.47% | -164.74% |
Free Cash Flow Margin | -60.52% | -72.20% | -23.69% | -56.95% | -8.39% | 6.96% |
EBITDA | -5,675 | -5,059 | -8,305 | -9,791 | -2,708 | 5,357 |
EBITDA Margin | -15.68% | -15.98% | -32.73% | -44.28% | -8.23% | 14.96% |
D&A For EBITDA | 1,656 | 1,484 | 1,870 | 1,402 | 2,625 | 7,248 |
EBIT | -7,331 | -6,543 | -10,175 | -11,193 | -5,333 | -1,891 |
EBIT Margin | -20.26% | -20.66% | -40.10% | -50.62% | -16.20% | -5.28% |
Advertising Expenses | - | 2.3 | 1.92 | 297.47 | 163.47 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.